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Symptoms of drug-associated interstitial lung disease (ILD) are nonspecific and can be difficult to distinguish from a number of
illnesses that commonly occur in patients with non-small-cell lung cancer (NSCLC) on therapy. Identification of drug involvement and
differentiation from other illnesses is problematic, although radiological manifestations and clinical tests enable many of the alternative
causes of symptoms in advanced NSCLC to be excluded. In lung cancer patients, high-resolution computed tomography (HRCT) is
more sensitive than a chest radiograph in evaluating the severity and progression of parenchymal lung disease. Indeed, the use of
HRCT imaging has led to the recognition of many distinct patterns of lung involvement and, along with clinical signs and symptoms,
helps to predict both outcome and response to treatment. This manuscript outlines the radiology of drug-associated ILD and its
differential diagnosis in NSCLC. An algorithm that uses clinical tests to exclude alternative diagnoses is also described.
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INTRODUCTION
The diagnosis of drug-associated interstitial lung disease (ILD)
involves three elements: clinical suspicion, differentiation from
other parenchymal lung diseases using computed tomography
(CT) and other clinical tests for alternative disease, and a
compatible histological pattern. This review article will discuss
the radiological evaluation of a patient with non-small-cell lung
cancer (NSCLC) suspected of suffering from drug-associated ILD,
the diagnosis and management of drug-associated ILD, and the
development of a diagnostic algorithm designed to distinguish
gefitinib (‘Iressa’)-associated ILD from other forms of parenchy-
mal disease.
SUSPICION OF DRUG-ASSOCIATED ILD IN PATIENTS
WITH NSCLC
The onset of drug-associated ILD during therapy for advanced
NSCLC usually occurs within a few weeks of the start of treatment
(Thomas et al, 2000; Gupta et al, 2002; Kudrik et al, 2002; Read
et al, 2002). Indeed, retrospective analysis of the first 152 patients
in Japan to experience gefitinib-associated ILD showed that 475%
of cases occurred within 3 months, with the majority of these
occurring within 4 weeks.
The symptoms of drug-associated ILD, as with all forms of the
condition, include rapidly developing breathlessness and a dry and
unproductive cough, together with fever (Thomas et al, 2000;
Gupta et al, 2002; Kudrik et al, 2002; Read et al, 2002). Such
symptoms are nonspecific and can occur with a large number
of common illnesses often associated with NSCLC, or they
may be due to cancer progression or lung cancer therapy.
These patients are also prone to pneumonia and many have
radiation-related injury as a result of prior treatment. Cardiovas-
cular causes of the symptoms, such as fluid overload, congestive
heart failure and pulmonary embolus, are not uncommon.
Differentiation of drug-associated ILD from these illnesses is
difficult and the diagnosis is usually made by exclusion. High-
resolution CT (HRCT) is recommended on first suspicion of ILD to
provide an assessment of the parenchymal nature of the cause of
symptoms.
RADIOLOGY OF DRUG-ASSOCIATED ILD
The radiological manifestations of drug-associated ILD, although
heterogeneous and nonspecific, enable many of the alternative
causes of symptoms in advanced NSCLC to be excluded. There is
no specific radiological pattern of parenchymal change connected
with drug-associated ILD. Furthermore, in the early stages of
disease, patients with symptoms secondary to drug reaction may
have a normal chest radiograph.
High-resolution CT allows a more precise assessment of the
presence, pattern and distribution of parenchymal and airway
abnormalities than a chest radiograph. It has the advantage over
lung biopsy of providing an overall view of the extent and pattern
of parenchymal involvement rather than being limited to a small
region, which may not be representative of the overall pattern of
disease. However, there is limited information on the correlation
between the findings on HRCT and histological patterns in
drug-associated lung disease. Data based on a small number of
cases suggest that the different histological patterns of drug
reaction are not reflected by distinctive HRCT findings (Cleverley
et al, 2002). *Correspondence: Professor NL Mu ¨ller; E-mail: nmuller@vanhosp.bc.ca
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radiological manifestations of drug-associated lung disease by the
use of the underlying histological pattern (Ellis et al, 2000; Myers
et al, 2003). Using such an approach, the most common
manifestations can be classified into diffuse alveolar damage,
hypersensitivity pneumonitis, organising pneumonia, nonspecific
interstitial pneumonia (NSIP) and eosinophilic pneumonia (other
less common drug reactions are not discussed here). Any one
histological pattern can be caused by a number of different drugs.
Furthermore, similar histology is found in other conditions that
are not associated with drug use, such as idiopathic interstitial
pneumonias, viral, bacterial and fungal pneumonia, pulmonary
haemorrhage or leukaemia and collagen vascular disease. Occa-
sionally, HRCT may demonstrate findings that are highly specific
for the diagnosis, including increased attenuation in amiodarone
lung and areas of fat attenuation in lipoid pneumonia.
Diffuse alveolar damage
Diffuse alveolar damage is characterised histologically by the
presence of alveolar airspace and interstitial oedema, hyaline
membrane formation and proliferation of type II pneumocytes
(Rossi et al, 2000; Cleverley et al, 2002). In relation to drug-
associated pulmonary disease, it occurs most commonly with
cytotoxic agents such as bleomycin and, less commonly, with
aspirin and narcotics (Rossi et al, 2000; Cleverley et al, 2002). The
corresponding radiological features are also found in adult
respiratory distress syndrome (ARDS). The chest radiograph
shows bilateral patchy or homogeneous airspace consolidation
involving mainly the middle and lower lung zones (Rossi et al,
2000; Cleverley et al, 2002). High-resolution CT demonstrates
extensive bilateral ground-glass opacities and dependent areas of
airspace consolidation (Rossi et al, 2000; Erasmus et al, 2002)
(Figure 1A).
Hypersensitivity pneumonitis
A number of drugs may result in hypersensitivity pneumonitis,
including methotrexate, cyclophosphamide and antidepressants
such as fluoxetine and amitriptyline (Ellis et al, 2000). The
radiological and HRCT findings are identical to those seen in
hypersensitivity pneumonitis secondary to the inhalation of
organic dust and consist of bilateral ground-glass opacities and/
or small poorly defined centrilobular nodular opacities (Ellis et al,
2000; Cleverley et al, 2002). The majority of patients also
demonstrate lobular areas of air trapping, although this is less
Figure 1 High-resolution CT images demonstrating radiology of drug-associated ILD. (A) A 77-year-old man with diffuse alveolar damage secondary to
amidarone; note the extensive bilateral ground-glass opacities, airspace consolidation and bilateral pleural effusions. (B) A 36-year-old woman with
hypersensitivity pneumonitis secondary to sertraline; note the extensive bilateral ground-glass opacities and lobular areas of air trapping (arrows).
(C) A 69-year-old man with BOOP-like reaction to amiodarone; note the mild reticulation and bilateral areas of consolidation and ground-glass opacities in a
predominantly peribronchial distribution. (D) A 47-year-old man with NSIP reaction to bleomycin; note the extensive bilateral ground-glass opacities with
mild superimposed reticulation. (E) A 47-year-old man with eosinophilic pneumonia reaction to dilantin; note the patchy bilateral areas of consolidation
involving the peripheral regions of the upper lobes.
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(Ellis et al, 2000) (Figure 1B).
Organising pneumonia
Organising pneumonia, also known as bronchiolitis obliterans
organising pneumonia (BOOP)-like reaction, has been reported
most frequently in association with methotrexate, cyclopho-
sphamide, gold, nitrofurantoin, amiodarone, bleomycin and
busulphan (Cleverley et al, 2002; Erasmus et al, 2002). The chest
radiograph shows patchy bilateral areas of consolidation, masses
or nodules, which may be symmetric or asymmetric (Mu ¨ller et al,
1990; Ellis et al, 2000). In a few patients, the disease manifests with
a lone mass. On HRCT, areas of consolidation often have a
predominantly peripheral or peribronchial distribution (Mu ¨ller
et al, 1990; Ellis et al, 2000) (Figure 1C).
Nonspecific interstitial pneumonia
Nonspecific interstitial pneumonia is one of the most common
forms of drug-associated pneumonitis. Nonspecific interstitial
pneumonia is characterised histologically by homogeneous alveo-
lar wall thickening by fibrous tissue and mononuclear inflamma-
tory cells. The reaction is seen in association with a variety of
drugs, the most common being methotrexate, amiodarone and
carmustine (Erasmus et al, 2002). The corresponding radio-
graphical and HRCT findings usually consist of patchy or diffuse
ground-glass opacities (Rossi et al, 2000; Erasmus et al, 2002)
(Figure 1D). On disease progression, there may be evidence of
fibrosis with development of a reticular pattern and traction
bronchiectasis. In some patients, the fibrosis is patchy in
distribution and predominantly peribronchovascular, a pattern
most commonly seen in patients receiving nitrofurantoin. Late
chemotherapy lung may predominate in the upper and lateral
parts of the lung.
Eosinophilic pneumonia
Eosinophilic pneumonia is characterised histologically by the
accumulation of eosinophils in the alveolar airspaces and
infiltration of the adjacent interstitial space by eosinophils and
variable numbers of lymphocytes and plasma cells. Peripheral
blood eosinophilia is present in p40% of patients. Eosinophilic
pneumonia secondary to drug reaction is seen most commonly in
association with methotrexate, sulphasalazine, para-aminosalicylic
acid, nitrofurantoin and nonsteroidal anti-inflammatory drugs.
Chest radiography and HRCT show bilateral airspace consolida-
tion, which tends to involve mainly the peripheral lung regions and
the upper lobes (Rossi et al, 2000; Cleverley et al, 2002) (Figure 1E).
DIFFERENTIAL DIAGNOSIS OF DRUG-ASSOCIATED
ILD IN NSCLC
Alternative diagnoses to drug-associated ILD in NSCLC include
progression of the cancer, infection, radiation-related lung injury,
fluid overload, congestive heart failure and pulmonary embolus.
Additionally, some lung cancer patients may develop BOOP or
other steroid-responsive inflammatory disorders that cannot be
clearly related to drug therapy. Other possible causes of dyspnoea
that do not give infiltrates include comorbid diseases such as
chronic obstructive pulmonary disease (COPD) and aspiration of
food and saliva (particularly in patients with vocal cord paralysis
or brain metastases).
In the USA, pulmonary embolism is particularly common in
patients with lung cancer, with as many as 20% of patients
estimated to develop a deep vein thrombosis or pulmonary
embolism during the course of their disease (Lieberman et al, 1961;
Sack et al, 1977; Lee and Levine, 2003).
Most episodes of pneumonia in patients with lung cancer are
due to bacteria. This is particularly the case when risk factors of
neutropenia, endobronchial lesions, underlying COPD and aspira-
tion are present. Although opportunistic infections are not
common, fungal infections should be considered if the patient
has received a high dose of corticosteroids. Viral infections with
herpes simplex, cytomegalovirus or respiratory syncytial virus may
also rarely result in pneumonia in patients who have received high-
dose corticosteroids or very intensive chemotherapy.
The development of lung fibrosis following radiation therapy is
well documented and is usually confined to the radiation port
(Abid et al, 2001; Aviram et al, 2001). With the use of three-
dimensional radiation portals, however, resulting infiltrates from
radiation may not result in the traditional straight-edged infiltrate
and may be more difficult to distinguish from other entities.
Investigations of dyspnoea in lung cancer patients
Patients with lung cancer who present with respiratory failure
should undergo systematic investigation. Pulmonary function
tests, such as measurement of forced expiratory volume in 1s,
carbon monoxide diffusing capacity and measurement of arterial
oxygen saturation with pulse oximetry, are commonly used. These
tests ascertain the type of defect, for example, obstructive or
restrictive ventilatory defects, which helps establish the cause, such
as an exacerbation of any underlying obstructive airways disease
versus interstitial disease. They also indicate the severity of the
disease that helps determine the need for further assessment and
treatment.
A standard chest CT scan is commonly performed to exclude a
diagnosis of disease progression or pulmonary embolism. How-
ever, as discussed previously, obtaining high-resolution cuts is
very helpful (HRCT) if drug-associated ILD is suspected.
Bronchoscopy is useful to evaluate some NSCLC patients with
dyspnoea to assess extension of the cancer and to exclude an
opportunistic infection using bronchioalveolar lavage. However,
the value of a bronchoscopy in establishing the diagnosis of drug-
associated ILD is less clear, since bronchioalveolar lavage is not
specific for drug-associated disease, and biopsies obtained by
transbronchial biopsy are small and often do not yield enough
tissue to make this distinction. Open lung biopsy is rarely
performed in NSCLC patients with respiratory distress since most
patients have advanced disease with a limited prognosis.
Furthermore, procedures requiring surgery are not usually
believed to arrive at a definitive diagnosis of drug-associated ILD.
Patients with mild symptoms or pulmonary function abnorm-
alities (such as a decrease in diffusing capacity of o20% from
baseline or no change in oxygen desaturation during exercise), or
with transitory or slight radiographical infiltrates are monitored
using pulmonary function tests, symptoms and usually CT scans.
Diagnostic evaluation and treatment for drug-related lung disease
is considered in those patients who experience dyspnoea at rest or
on mild exertion, have a X20% decrease in carbon monoxide
diffusing capacity, or experience oxygen desaturation at rest or
during exercise. Patients whose radiographical infiltrates are
extensive or progressive are also considered for therapy.
DIAGNOSTIC ALGORITHMS FOR ILD IN PATIENTS
WITH NSCLC
Retrospective analysis of the adverse-event reports from patients
diagnosed with ILD following gefitinib treatment is also difficult as
there is often limited or heterogeneous clinical information, no
pathology result and no access to the results of radiological
investigations.
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the accuracy of the reports of drug-associated ILD among Japanese
patients receiving gefitinib. This approach to differential diagnosis
used an algorithm developed to aid early diagnosis of drug-
associated ILD in clinical practice.
The algorithm used both radiological and clinical evidence to
exclude alternative diagnoses, such as infection, tumour progres-
sion, heart failure and pulmonary embolism, to arrive at a
presumptive diagnosis of drug-associated ILD (Figure 2; Table 1).
Patients were categorised based on the strength of evidence
supporting the diagnosis of drug-associated ILD (category 1, good
supporting evidence for ILD; category 2, limited supporting
evidence for ILD; category 3, no supporting evidence for ILD).
Retrospective use of the algorithm
In the first assessment, adverse-event reports from Japanese
patients receiving gefitinib for NSCLC were evaluated using the
algorithm, with available clinical information and radiographical
reports but without access to chest radiographs or HRCT films.
These findings were then compared with those of a second
assessment, conducted by an independent panel of expert
radiologists and physicians. The panel assessed the radiological
and clinical findings for the same patient population using a set of
standardised criteria (Cleverley et al, 2002).
The initial 152 reported patients with NSCLC in Japan who had
experienced adverse events involving the lungs while receiving
treatment with gefitinib were included in the first assessment of
the algorithm. Of these, 135 were included in the second
assessment because radiological examinations, including 47 with
CT imaging, were available. Approximately 20% of these patients
(23 out of 135) were considered by the expert panel not to have
drug-associated ILD, highlighting the difficulty in diagnosing
drug-associated ILD in patients with NSCLC.
These results were then compared with those obtained using the
algorithm. A large proportion (17 out of 23) of patients not
Symptoms of:
    worsening breathlessness
    increasing cough
    fever
On physical examination:
    'crackles' on chest examination
    increased respiratory rate
    increased temperature
and/or
Parenchymal shadows on
chest radiograph?
Presence of ground-glass
shadows and/or linear
opacities on HRCT scan?
Elevated WBC count 
or identification of a
pathogen
Sputum exam and
culture, blood and
urine culture (bacterial
antigens) and PCR
Blood tests:
WBC,
Hb and urea
Fibre-optic
bronchoscopy
with lavage and
possibly trans- 
bronchial biopsy
ECG and
echocardiogram
V/Q lung scan
or contrast
CT scan
No evidence of
carcinomatosis,
pathogens or 
granulomas
Left ventricular
failure and/or
ischaemic heart
disease
Pulmonary embolus
Conduct further tests
Diagnose ILD
Failed
response to
broad spectrum
antibiotics
Worsening of
chest radiographs
or symptoms
Failed
response to
therapy
Failed
response to
therapy
Close monitoring of lung
function, symptoms and
signs
Initial 
presentation
Radiological
evaluation
Further tests
Findings
Next steps
Yes
Yes
No
WBC = white blood cell; Hb = haemoglobin; PCR = polymerase chain reaction; ECG = electrocardiogram
Figure 2 Diagnostic algorithm of gefitinib-associated ILD in Japanese patients with NSCLC.
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categorised as having ‘good’ or ‘limited’ supporting evidence for
drug-associated ILD. The initial algorithm based on the terminol-
ogy used in radiology reports, without considering differential
diagnosis criteria, was not adequate. Infection, heart failure and
tumour progression can be differentially diagnosed and excluded
using additional radiological clinical data.
Therefore, the algorithm is now used to enable the clinician to
make a diagnosis having first undertaken all the necessary steps in
the clinical examination and investigation. This approach is
applied to the prospective nested case–control study to investigate
the relative risk and risk factors for ILD in NSCLC patients in
Japan treated with and without gefitinib. An independent case
review board will review each reported case of ILD using the
information gathered from the algorithm.
MANAGEMENT OF ACUTE RESPIRATORY DISTRESS
IN PATIENTS WITH LUNG CANCER
General principles in the management of acute respiratory distress
in patients with lung cancer are influenced by the multiple causes
of respiratory failure that are associated with cancer, lung cancer
therapy and the presence of comorbid disease. In addition, the
diagnosis may remain uncertain, even when invasive procedures
are performed, and empirical therapy for the likely causes is
frequently given. Finally, respiratory failure in patients with cancer
results in high mortality (Groeger et al, 1999) requiring aggressive
assessment and therapy.
Treatment of drug-associated ILD
There are no firm guidelines for the treatment of drug-associated
ILD and therapy tends to be on an empirical basis. Withdrawal of
the drug suspected of causing the ILD is the first step in treatment.
For patients in respiratory failure, high-dose methylprednisolone
(250mg four times a day i.v.) for several days is commonly
used. If the patient responds, then the dose is reduced
(0.5–1mgkg
 1day
 1 orally) for several weeks before being
gradually tapered. For patients in respiratory distress, methyl-
prednisolone (1mgkg
 1day
 1 or 60mgday
 1) is commonly used,
again with gradual dose reduction. Low-dose methylprednisolone
(10–20mg) is prescribed for patients with mild radiographical or
pulmonary function abnormalities, particularly if oral corticoster-
oids are contraindicated (White and Stover, 1984; Baughman et al,
1994; American Thoracic Society, 2002).
Immunosuppressive agents such as azathioprine have been used
as steroid-sparing agents in the treatment of drug-associated ILD,
particularly in chronic cases of bleomycin-associated ILD (Maher
and Daly, 1993). These agents are useful for patients in whom
corticosteroids cannot be tapered or who cannot tolerate
corticosteroids. It is also advisable to avoid combining agents
associated with ILD, such as bleomycin and possibly mitomycin,
with other agents that cause lung damage, such as oxygen and
radiation, as this may result in worsening of the lung damage. If
radiotherapy is indicated in a patient who has experienced mild
bleomycin toxicity, then concomitant low-dose corticosteroid may
minimise any further lung damage. Following resolution of the
drug-associated ILD, some patients are susceptible to exacerba-
tions on subsequent insults (e.g. during a respiratory infection)
and may require further treatment.
In cancer patients, drug-associated ILD is most commonly
observed during mitomycin, paclitaxel, docetaxel or gemcitabine
therapy. Table 2 outlines the types of injury reported with these
agents and their response to therapy (Buzdar et al, 1980; Chang
et al, 1986; Goldberg and Vannice, 1995; Rivera et al, 1995;
Ramanathan and Belani, 1996; Bookman et al, 1997; Merad et al,
1997; Piccart et al, 1997; Semb et al, 1998; Vander Els and Miller,
1998; Dunsford et al, 1999; Thomas et al, 2000; Fogarty et al, 2001;
Read et al, 2002; Barlesi et al, 2004). Acute pneumonitis, both
interstitial and noncardiac pulmonary oedema pattern, has been
observed with mitomycin. Response to high-dose methylpredni-
solone has been reported within 24–48h of therapy; however,
approximately 60% of patients developed ongoing and persistent
lung disease (Rivera et al, 1995). Chronic pneumonitis, similar to
bleomycin-type pneumonitis, has also been reported during
mitomycin therapy, which responded to prednisone therapy
(Buzdar et al, 1980; Chang et al, 1986). As with bleomycin, it has
been suggested that oxygen therapy be avoided during mitomycin
therapy, although the evidence for this is not as established as that
for bleomycin (Klein and Wilds, 1983).
Infusion hypersensitivity is very common during paclitaxel
therapy. Pretreatment with an antihistamine, a corticosteroid and
an H2 blocker largely prevents or ameliorates this reaction
(Bookman et al, 1997). Mild interstitial pneumonitis with
transitory infiltrates has also been reported; observation or low-
dose corticosteroids resulted in a good response, even when this
occurred in conjunction with radiotherapy (Goldberg and
Vannice, 1995; Ramanathan and Belani, 1996).
Table 1 Nonradiological tests for ILD
Alternative
diagnosis Test
Infection Erythrocyte sedimentation rate
C-reactive protein levels
White blood cell count and differential count of leucocytes
Sputum/blood cultures
Serum antibody tests for pathogens, for example, fungal infection,
beta-D-glutan, clamydia, cytomegalovirus, etc
PCR in blood, other body fluids, etc
Cancer Tumour markers
progression Changes in pleural effusion and pericardial effusion
Biopsy evidence
Association KL-6, SP-A, SP-D or serum soluble interleukin-2 receptor levels
with ILD LDH levels
Respiratory function tests: SpO2, with or without exercise; %vital
capacity, FEV1/forced vital capacity; and %DLCO
Bronchioalveolar lavage combined with fibrescopic transbronchial
lung biopsy
Renal failure Blood urea nitrogen levels
Creatinine levels
Sodium, potassium and chloride levels
Heart failure Electrocardiogram for myocardial infarction
Reduced left ventricle ejection fraction on echocardiogram
Anaemia Red blood cell count
Haemoglobin levels
Pulmonary Proximal obstruction of pulmonary artery on contrast CT scan
embolus Perfusion lung scan, lung scintigraphy
Blood tests for thrombophilia: platelet count, fibrinogen
degradation product levels, prothrombin time and activated partial
thromboplastin time
LDH levels
Histology from lung biopsy or specimens obtained at autopsy
PCR¼polymerase chain reaction; LDH¼lactate dehydrogenase; SpO2¼arterial
oxygen saturation with pulse oximetry; FEV1¼forced expiratory volume in 1s;
DLCO¼carbon monoxide diffusing capacity and CT¼computed tomography.
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common and is associated with dyspnoea. This reaction can be
prevented by dexamethasone (Piccart et al, 1997; Semb et al, 1998).
Interstitial pneumonitis and ARDS-like pattern have also been
reported with docetaxel, particularly when it is used in combina-
tion with radiotherapy or gemcitabine. Both reactions respond well
to corticosteroid therapy; however, when docetaxel is used in
combination with radiotherapy or gemcitabine, the response to
corticosteroid therapy can be variable to poor, with some deaths
reported (Merad et al, 1997; Dunsford et al, 1999; Read et al, 2002).
Self-limiting dyspnoea is common during gemcitabine therapy.
Additionally, many patients experience a mild capillary leak
throughout the lung, similar to that seen in ARDS. However, these
patients are asymptomatic and have normal pulmonary function;
therefore, gemcitabine therapy can be continued without the need
for corticosteroids. Gemcitabine-associated ILD has also been
reported and the response to corticosteroid therapy is variable. As
with docetaxel, more deaths due to ILD have been reported when
gemcitabine is used in combination with other therapies (radio-
therapy or chemotherapy) (Vander Els and Miller, 1998; Dunsford
et al, 1999; Thomas et al, 2000; Fogarty et al, 2001; Barlesi et al,
2004).
Re-challenge of drug therapy in suspected cases of ILD
In the management of patients with NSCLC, it is often necessary to
treat patients with an agent that has been previously associated
with ILD. In this scenario, it is important to consider the patient’s
previous response to that therapy, the severity of the lung damage
and the respiratory distress, the presence of fibrosis and the
previous response to corticosteroid therapy. For some patients, the
benefits may outweigh the risks and therapy may be re-instituted
with concomitant low-dose prednisone (10–20mgday
 1); how-
ever, for some patients and/or agents the potential for causing
further lung damage may be too great.
SUMMARY
In summary, lung cancer patients receiving systemic therapy
frequently develop dyspnoea and infiltrates. It is difficult to make a
specific diagnosis in most cases because of the difficulty of
performing invasive procedures in this patient population.
Radiological assessment, and HRCT in particular, can play a key
role in establishing a diagnosis of drug-associated ILD; however, in
the vast majority of cases, the radiological manifestations of drug-
associated pulmonary injury are nonspecific, making an accurate
diagnosis difficult. Corticosteroids are indicated for suspected
drug-associated ILD; however, the outcome is variable unless the
patient develops respiratory failure, in which case the mortality is
high.
As a result, clinicians are reluctant to withhold corticosteroid
therapy if there is any indication of drug toxicity, further
complicating the diagnosis. However, once a patient responds to
corticosteroid therapy, the decision to re-institute a drug suspected
of causing ILD is made on an individual basis. In this article we
described an algorithm developed to assess the incidence of drug-
associated ILD in Japanese patients receiving gefitinib for NSCLC.
Such an algorithm, once validated, may be a useful tool in the
differential diagnosis of ILD in patients with cancer and help
clarify some of the apparent discrepancies in the incidence and
reporting of ILD.
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